Quality of Life in Long-Term Testicular Cancer Survivors With Compensated Leydig Cell Dysfunction

To clarify if testicular cancer (TC) survivors with compensated Leydig cell (LC) dysfunction have impaired quality of life, we studied 147 long-term survivors of TC and analyzed quality-of-life outcomes. Sixty TC survivors had compensated LC dysfunction, and 87 TC survivors had normal LC function. Compensated LC dysfunction in TC survivors was not associated with impaired overall self-evaluated quality of life. Background: Compensated Leydig cell (LC) dysfunction, defined by elevated serum levels of luteinizing hormone (LH) in combination with normal total testosterone levels, is common in testicular cancer (TC) survivors. The association between this condition and quality of life is unknown. We aimed to clarify if TC survivors with compensated LC dysfunction have impaired quality of life. Patients and Methods: In total, 147 long-term TC survivors were included. On the basis of a single measurement of testosterone and LH, compensated LC dysfunction was defined by age-adjusted levels of LH above normal range combined with testosterone levels within the normal range. Quality-of-life outcomes including sexual function, anxiety and depression, fatigue, and overall self-evaluated quality of life were compared between patients with and without compensated LC dysfunction with adjustment for age. Results: In total, 60 TC survivors had compensated LC dysfunction and 87 TC survivors had normal LC function. TC survivors with compensated LC dysfunction had lower serum levels of total testosterone (11 vs. 13 nmol/L, P= .016). There were no significant differences in the investigated quality-of-life outcomes (anxiety, depression, sexual function, fatigue) between the 2 groups. Conclusion: Compensated LC dysfunction in TC survivors was not associated with symptoms of depression, anxiety, sexual dysfunction, fatigue, or impaired overall self-evaluated quality of life. Limitations include the few cases of symptoms of depression (n = 7). Our findings do not suggest that testosterone substitution is indicated in TC survivors with compensated LC dysfunction. (C) 2018 Elsevier Inc. All rights reserved.